Scilex Holding (SCLX) Q4 2024 earnings summary

Executive summary

• Focuses on non-opioid pain management, with three commercial products: ZTlido (lidocaine topical system), ELYXYB (celecoxib oral solution), and GLOPERBA (liquid colchicine).

• Pipeline includes SEMDEXA (SP-102, dexamethasone gel for sciatica), SP-103 (high-dose lidocaine patch), and SP-104 (low-dose naltrexone for fibromyalgia).

• ZTlido remains the primary revenue driver, with ELYXYB and GLOPERBA in early commercialization stages.

• Company reported a net loss and faces substantial doubt about its ability to continue as a going concern.

Financial highlights

• Net revenue for 2024 was $56.6 million, up from $46.7 million in 2023, driven by increased sales of ZTlido and ELYXYB, and the launch of GLOPERBA.

• Net loss for 2024 was $72.8 million, compared to $114.3 million in 2023.

• Cash and cash equivalents as of December 31, 2024, were $3.3 million.

• Accumulated deficit reached $563.1 million at year-end 2024.

• Cost of revenue increased to $16.7 million in 2024, reflecting higher royalties and product costs.

• Legal settlements contributed $9.4 million in gains in 2024.

Outlook and guidance

• Management expects continued losses and negative cash flows, with a need for substantial additional funding.

• Plans to seek additional capital through equity, debt, collaborations, or strategic transactions.

• Ongoing focus on expanding sales of ZTlido, ELYXYB, and GLOPERBA, and advancing late-stage pipeline candidates.